和铂医药-B（02142）今日盘中股价大幅上涨5.28%，引起了市场的广泛关注。
消息面上，公司于前一交易日盘后公布了2025年度业绩报告，数据显示其业绩表现极为强劲。报告期内，公司总收入约1.58亿美元，同比增长超过314%；年内溢利达到9222.1万美元，同比大幅增长约32.63倍。公司现金及现金等价物也显著增长，显示出强大的财务实力。
此外，公司宣布全面迈入3.0战略阶段，由三大增长引擎协同驱动，包括打造AI驱动的全球抗体药物发现平台、与跨国制药公司建立深度战略合作，以及最大化在自身免疫性疾病和肿瘤等领域的中后期资产价值。公司与阿斯利康、辉瑞等全球制药巨头的合作不断深化，多个创新药物管线也取得了积极进展，这些因素共同增强了投资者对公司未来增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.